BioRestorative Therapies Inc
BRTX1.150USD
-0.030-2.54%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
9.17MMarket Cap
LossP/E TTM
More Details of BioRestorative Therapies Inc Company
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
BioRestorative Therapies Inc Info
Ticker SymbolBRTX
Company nameBioRestorative Therapies Inc
IPO dateJul 11, 2001
CEOAlstodt (Lance)
Number of employees11
Security typeOrdinary Share
Fiscal year-endJul 11
Address40 Marcus Drive
CityMELVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code11747
Phone16317608100
Websitehttps://www.biorestorative.com/
Ticker SymbolBRTX
IPO dateJul 11, 2001
CEOAlstodt (Lance)
Company Executives of BioRestorative Therapies Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Lance Alstodt
Mr. Lance Alstodt
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
187.50K
+9.09%
Mr. Francisco Silva
Mr. Francisco Silva
Vice President - Research & Development, Secretary, Director
Vice President - Research & Development, Secretary, Director
179.61K
+6.98%
Mr. Robert E. Kristal
Mr. Robert E. Kristal
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nickolay Kukekov, Ph.D.
Dr. Nickolay Kukekov, Ph.D.
Independent Director
Independent Director
--
--
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
Independent Director
Independent Director
--
--
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Independent Director
Independent Director
--
--
Mr. Stephen Kilmer
Mr. Stephen Kilmer
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Lance Alstodt
Mr. Lance Alstodt
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
187.50K
+9.09%
Mr. Francisco Silva
Mr. Francisco Silva
Vice President - Research & Development, Secretary, Director
Vice President - Research & Development, Secretary, Director
179.61K
+6.98%
Mr. Robert E. Kristal
Mr. Robert E. Kristal
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nickolay Kukekov, Ph.D.
Dr. Nickolay Kukekov, Ph.D.
Independent Director
Independent Director
--
--
Mr. David A. (Dave) Rosa
Mr. David A. (Dave) Rosa
Independent Director
Independent Director
--
--
Mr. Patrick F. Williams
Mr. Patrick F. Williams
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Broadrick (Dale)
10.41%
Hale (Morrison Todd)
7.72%
Auctus Fund Management, L.L.C.
4.89%
Alstodt (Lance)
2.11%
Silva (Francisco)
2.02%
Other
72.85%
Shareholders
Shareholders
Proportion
Broadrick (Dale)
10.41%
Hale (Morrison Todd)
7.72%
Auctus Fund Management, L.L.C.
4.89%
Alstodt (Lance)
2.11%
Silva (Francisco)
2.02%
Other
72.85%
Shareholder Types
Shareholders
Proportion
Individual Investor
21.90%
Investment Advisor
6.57%
Hedge Fund
1.24%
Investment Advisor/Hedge Fund
0.85%
Research Firm
0.71%
Other
68.73%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
33
831.79K
10.80%
--
2025Q3
36
831.79K
12.45%
+131.24K
2025Q2
37
700.56K
16.87%
-246.75K
2025Q1
35
947.31K
18.24%
-314.80K
2024Q4
37
964.85K
18.52%
+11.43K
2024Q3
36
953.42K
18.27%
+34.26K
2024Q2
33
901.47K
13.36%
-128.84K
2024Q1
34
1.03M
11.71%
+237.42K
2023Q4
32
674.05K
17.37%
-49.21K
2023Q3
32
923.26K
19.30%
+114.30K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Broadrick (Dale)
923.90K
11.58%
--
--
Jul 31, 2025
Hale (Morrison Todd)
645.00K
8.08%
+75.00K
+13.16%
Feb 27, 2025
Auctus Fund Management, L.L.C.
434.15K
5.44%
-887.00
-0.20%
Jul 31, 2025
Alstodt (Lance)
171.87K
2.15%
--
--
Jul 31, 2025
Silva (Francisco)
167.90K
2.1%
--
--
Jul 31, 2025
The Vanguard Group, Inc.
29.73K
0.37%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
54.26K
0.68%
-5.74K
-9.56%
Jun 30, 2025
Wealth Alliance
40.00K
0.5%
--
--
Jun 30, 2025
StoneX Group Inc.
37.74K
0.47%
-13.45K
-26.27%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of BioRestorative Therapies Inc?
The top five shareholders of BioRestorative Therapies Inc are:
Broadrick (Dale) holds 923.90K shares, accounting for 11.58% of the total shares.
Hale (Morrison Todd) holds 645.00K shares, accounting for 8.08% of the total shares.
Auctus Fund Management, L.L.C. holds 434.15K shares, accounting for 5.44% of the total shares.
Alstodt (Lance) holds 171.87K shares, accounting for 2.15% of the total shares.
Silva (Francisco) holds 167.90K shares, accounting for 2.10% of the total shares.
Broadrick (Dale) holds 923.90K shares, accounting for 11.58% of the total shares.
Hale (Morrison Todd) holds 645.00K shares, accounting for 8.08% of the total shares.
Auctus Fund Management, L.L.C. holds 434.15K shares, accounting for 5.44% of the total shares.
Alstodt (Lance) holds 171.87K shares, accounting for 2.15% of the total shares.
Silva (Francisco) holds 167.90K shares, accounting for 2.10% of the total shares.
What are the top three shareholder types of BioRestorative Therapies Inc?
The top three shareholder types of BioRestorative Therapies Inc are:
Broadrick (Dale)
Hale (Morrison Todd)
Auctus Fund Management, L.L.C.
Broadrick (Dale)
Hale (Morrison Todd)
Auctus Fund Management, L.L.C.
How many institutions hold shares of BioRestorative Therapies Inc (BRTX)?
As of 2025Q4, 33 institutions hold shares of BioRestorative Therapies Inc, with a combined market value of approximately 831.79K, accounting for 10.80% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.65%.
What is the biggest source of revenue for BioRestorative Therapies Inc?
In --, the -- business generated the highest revenue for BioRestorative Therapies Inc, amounting to -- and accounting for --% of total revenue.
